Management of Antibiotic-Resistant Infection: Perspectives from Vietnam

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2019 Apr 23

PMID 31009957

Citations 18

Authors

Vu Van Khien

Duong Minh Thang

Tran Manh Hai

Nguyen Quang Duat

Pham Hong Khanh

Dang Thuy Ha

Tran Thanh Binh

Ho Dang Quy Dung

Tran Thi Huyen Trang

Yoshio Yamaoka

Affiliations

Soon will be listed here.

Abstract

Antibiotic resistance is the most important factor leading to the failure of eradication regimens. This review focuses on the prevalence of primary and secondary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug in Vietnam. We searched the PubMed, EMBASE, Vietnamese National Knowledge Infrastructure, and Vietnamese Biomedical databases from January 2000 to December 2016. The search terms included the following: infection, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug) resistance in Vietnam. The data were summarized in an extraction table and analyzed manually. Finally, Excel 2007 software was used to create charts. Ten studies (three studies in English and seven in Vietnamese) were included in this review. A total of 308, 412, 523, 408, 399, and 268 strains were included in this review to evaluate the prevalence of primary resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance, respectively. Overall, the primary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 15.0%, 34.1%, 69.4%, 27.9%, 17.9% and 48.8%, respectively. Secondary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 9.5%, 74.9%, 61.5%, 45.7%, 23.5% and 62.3%, respectively. In Vietnam, primary and secondary resistance to is increasing over time and affects the effectiveness of eradication.

Citing Articles

: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.

Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.

PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.

Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.

Islam J, Yano Y, Okamoto A, Matsuda R, Shiraishi M, Hashimoto Y Sci Rep. 2024; 14(1):12066.

PMID: 38802465 PMC: 11130178. DOI: 10.1038/s41598-024-62200-1.

Efficacy and safety of seven Chinese patent medicines combined with conventional triple/quadruple therapy for -positive peptic ulcers: a systematic review and network meta-analysis.

Jiang Z, Deng B, Zhang Y, Li Y, Yu Z, Deng H BMJ Open. 2024; 14(4):e074188.

PMID: 38684278 PMC: 11086278. DOI: 10.1136/bmjopen-2023-074188.

Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).

Aumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone R PLoS One. 2023; 18(11):e0294403.

PMID: 38033026 PMC: 10688878. DOI: 10.1371/journal.pone.0294403.

Treatment of infection and gastric ulcer: Need for novel Pharmaceutical formulation.

Gupta A, Shetty S, Mutalik S, Chandrashekar H R, K N, Mathew E Heliyon. 2023; 9(10):e20406.

PMID: 37810864 PMC: 10550623. DOI: 10.1016/j.heliyon.2023.e20406.

References

Debets-Ossenkopp Y, Herscheid A, Pot R, Kuipers E, Kusters J, Vandenbroucke-Grauls C . Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999; 43(4):511-5. DOI: 10.1093/jac/43.4.511. View

Mao H, Lak B, Long T, Chung N, Thang D, Hop T . Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. Aliment Pharmacol Ther. 2000; 14(1):97-101. DOI: 10.1046/j.1365-2036.2000.00659.x. View

Sugiyama T, Sakaki N, KOZAWA H, Sato R, Fujioka T, Satoh K . Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther. 2002; 16 Suppl 2:187-90. DOI: 10.1046/j.1365-2036.16.s2.17.x. View

Jenks P . Causes of failure of eradication of Helicobacter pylori. BMJ. 2002; 325(7354):3-4. PMC: 1123549. DOI: 10.1136/bmj.325.7354.3. View

Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F . Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2002; 17(1):99-109. DOI: 10.1046/j.1365-2036.2003.01396.x. View

Blaser M, Atherton J . Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004; 113(3):321-33. PMC: 324548. DOI: 10.1172/JCI20925. View

Wheeldon T, Granstrom M, Hoang T, Phuncarg D, Nilsson L, Sorberg M . The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19(12):1315-21. DOI: 10.1111/j.1365-2036.2004.01959.x. View

Megraud F . H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9):1374-84. PMC: 1774187. DOI: 10.1136/gut.2003.022111. View

Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T . Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992; 102(3):760-6. DOI: 10.1016/0016-5085(92)90156-s. View

10.

Hoang T, Bengtsson C, Phung D, Sorberg M, Granstrom M . Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin Diagn Lab Immunol. 2005; 12(1):81-5. PMC: 540201. DOI: 10.1128/CDLI.12.1.81-85.2005. View

11.

Iacopini F, Crispino P, Paoluzi O, Consolazio A, Pica R, Rivera M . One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis. 2005; 37(8):571-6. DOI: 10.1016/j.dld.2005.03.007. View

12.

Nguyen B, Nguyen K, Phung C, Kremp O, Kalach N, Dupont C . Prevalence of and factors associated with Helicobacter pylori infection in children in the north of Vietnam. Am J Trop Med Hyg. 2006; 74(4):536-9. View

13.

Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H . Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect. 2006; 135(1):171-6. PMC: 2870552. DOI: 10.1017/S0950268806006613. View

14.

Nguyen V, Nguyen G, Phung D, Okrainec K, Raymond J, Dupond C . Intra-familial transmission of Helicobacter pylori infection in children of households with multiple generations in Vietnam. Eur J Epidemiol. 2006; 21(6):459-63. DOI: 10.1007/s10654-006-9016-y. View

15.

Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2006; 56(6):772-81. PMC: 1954853. DOI: 10.1136/gut.2006.101634. View

16.

Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y . Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007; 25(7):805-12. DOI: 10.1111/j.1365-2036.2007.03268.x. View

17.

Chey W, Wong B . American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8):1808-25. DOI: 10.1111/j.1572-0241.2007.01393.x. View

18.

Vakil N, Megraud F . Eradication therapy for Helicobacter pylori. Gastroenterology. 2007; 133(3):985-1001. DOI: 10.1053/j.gastro.2007.07.008. View

19.

Graham D, Adam E, Reddy G, Agarwal J, Agarwal R, Evans Jr D . Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991; 36(8):1084-8. DOI: 10.1007/BF01297451. View

20.

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S . Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372(9636):392-7. DOI: 10.1016/S0140-6736(08)61159-9. View